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The study was a randomised double-blind study. Patients were randomised in blocks of four if they successfully weaned from cardiopulmonary bypass (CPB) with cardiac index > 2.0 L.min (?-1).m(?-2). To maintain a double-blind protocol, each patient received 2 infusions simultaneously at an identical rate determined by the pharmacist who prepared the study medications. Patients in the propofol group received an infusion of propofol plus an infusion of normal saline (placebo) whereas patients randomised to the midazolam group received an infusion of midazolam plus an infusion of intralipid solution (placebo). All drugs or placebo were prepared in identical bags. Appropriate dilution of propofol and midazolam was made to obtain comparable infusion rates. The follow-up period was 16 hours after cessation.
Analysis of effectiveness
The analysis of the study was based on treatment completers only. The primary health outcomes used in the analysis were the efficacy of postoperative sedation and early extubation as indicated by duration of operation and of CPB, discharge time, level of sedation, preoperative morphine dose and blood loss. The groups were shown to be comparable in terms of age, sex, weight, height, and type and duration of operation.
Effectiveness results
The duration of operation (minutes) and duration of CPB (minutes) for the midazolam group were 191.2 (+/-34.0) and 72.2 (+/-24.6) respectively, and for the propofol group, were 184.0 (+/-32.5) and 63.5 (+/-16.8), respectively. ICU and hospital discharge time (days) for the midazolam group were 3.9 (+/-1.7) and 7.8 (+/-2.7) respectively and for the propofol group, were 3.7 (+/-1.7) and 7.2 (+/-1.7) respectively.
The average infusion rate of midazolam was 0.25 (+/-0.02 micrograms.kg(-1).min(-1), range: 0.23 -0.48) while that of propofol was 10.6 (+/-2.9micrograms.kg(-1).min(-1), range: 7.1 -32.4). In the midazolam group, 65.4% of the sedation time was spent at the desired level against 67% in the propofol group (not significant). The average total dose of morphine during the first 4 hours after surgery was 4.9 (+/-3.9mg) for midazolam and 3.9 (+/-2.5mg) for propofol (not significant). In the midazolam group, 40% of the patients received nitroprusside and 70% received nitroglycerine against 33% and 67% in the propofol group (not significant). Blood loss (ml) for the first 3 hours was 367.6 (+/-225.1) for midazolam and 345.8 (+/-243.8) for propofol and total blood loss was 885.0 (+/-652.2) and 890.3 (+/-656.1) respectively.
Clinical conclusions
No differences were found between the two groups for the time spent at each level of sedation, number of infusion rate adjustments, amount of analgesic and vasoactive drugs, times to awakening and extubation. No patient required tracheal reintubation.
Measure of benefits used in the economic analysis
The primary health outcomes used in the analysis were decreased mortality and morbidity. The indicators used were duration of operation and of CPB, discharge time, level of sedation, preoperative morphine dose and blood loss.
Direct costs
Infusion costs were calculated as the product of the mean total study drug multiplied by acquisition cost, and the range of infusion costs was calculated as the product of the range of total study drug administration multiplied by acquisition cost.
Statistical analysis of costs
Statistical analysis was performed using t-test for normally distributed numerical data. Chi-square and Fisher's exact test were used for nominal data. A P<0.01 was applied to costs. Mean and standard deviations were also used in the analysis.
